SPONSOR
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Total Trials
8
Recruiting
8
Phases
Phase 2, Phase 3, EARLY_Phase 1, Phase 2
Conditions studied: Peripheral T Cell LymphomaChronic Liver Disease (CLD)Liver FibrosisRetinal DystrophyPancreatic NeoplasmsHepatocellular Carcinoma (HCC)Prostate Cancer Metastatic DiseasePelvic Organ Prolapse (POP)Stress Urinary Incontinence (SUI)Gastric Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine is a clinical research sponsor with 8 registered studies on ClinicalTrials.gov, of which 8 are actively recruiting participants. Research covers conditions including Peripheral T Cell Lymphoma, Chronic Liver Disease (CLD), Liver Fibrosis, Retinal Dystrophy.
The trial portfolio spans Phase 2, Phase 3, EARLY_Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
How many clinical trials has Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine sponsored?
ClinicalMetric currently tracks 8 clinical trials sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, of which 8 are actively recruiting participants. These trials cover conditions including Peripheral T Cell Lymphoma, Chronic Liver Disease (CLD), Liver Fibrosis. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine research focus on?
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine clinical trials span Peripheral T Cell Lymphoma, Chronic Liver Disease (CLD), Liver Fibrosis, Retinal Dystrophy, Pancreatic Neoplasms, and additional conditions. The research pipeline includes Phase 2, Phase 3, EARLY_Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine clinical trial?
To participate in a Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine trials with current recruitment status updated daily.
Clinical Trials by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT07389616 Phase 2, Phase 3
Recruiting
A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
Peripheral T Cell Lymphoma
NCT07588854
Recruiting
Correlation Of EUS-SWQ And Liver Fibrosis Pathology In Chronic Liver Disease
Chronic Liver Disease (CLD)
NCT07063030 EARLY_Phase 1
Recruiting
A Study of LX107 Gene Therapy in AIPL1-IRD Patients
Retinal Dystrophy
NCT06532617 Phase 2
Recruiting
Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer
Pancreatic Neoplasms
NCT06652243 EARLY_Phase 1
Recruiting
Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
NCT06832774 Phase 2
Recruiting
Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients
Prostate Cancer Metastatic Disease
NCT07601282
Recruiting
Development and Validation of a Risk Prediction Model for De Novo Stress Urinary Incontinence After Pelvic Floor Reconstruction Surgery
Pelvic Organ Prolapse (POP)
NCT05536102 Phase 2
Recruiting
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
Gastric Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology